CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Portfolio Pulse from
Capricor Therapeutics' stock rose by 8% following the completion of the rolling submission of the Biologics License Application (BLA) for its lead drug, deramiocel, aimed at treating Duchenne muscular dystrophy (DMD) cardiomyopathy in the US.
January 03, 2025 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics' stock increased by 8% after completing the BLA submission for deramiocel, a treatment for DMD cardiomyopathy.
The completion of the BLA submission is a significant milestone for Capricor, indicating progress towards potential FDA approval. This news likely boosted investor confidence, leading to an 8% increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100